Capricor Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases, has announced its participation in three major upcoming investor conferences. The company will be presenting at:

• The Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) on February 12, 2025, from 12:00-12:30 p.m. ET
• The Barclays 27th Annual Global Healthcare Conference in Miami, FL (March 11-13, 2025)
• The 37th Annual ROTH Conference in Dana Point, CA (March 16-18, 2025)

During these conferences, Capricor's management will provide updates on their lead program, deramiocel, for treating Duchenne muscular dystrophy (DMD), along with general scientific and corporate updates.

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to participate in the following upcoming investor conferences.

Event:	Oppenheimer 35thAnnual Healthcare Life Sciences Conference (Virtual)
Date:	February 12, 2025 from 12:00-12:30 p.m. ET
Webcast Link	Click here
Event:	Barclays 27thAnnual Global Healthcare Conference (Miami, FL)
Date:	March 11-13, 2025
Event:	37thAnnual ROTH Conference (Dana Point, CA)
Date:	March 16-18, 2025

Capricor management will present updates on its lead program of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) as well as provide other general scientific and corporate updates. For further information on these presentations, please visit Capricor's website at http://capricor.com/news/events/.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently in late-stage development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and Twitter.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; statements about our financial outlook; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; potential future agreements; scope, duration, validity and enforceability of intellectual property rights; future revenue streams and projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 11, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on November 14, 2024. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.

For more information, please contact:

Capricor Media Contact:
Raquel Cona
KCSA Strategic Communications
rcona@kcsa.com
212.896.1204

Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755

FAQ

What investor conferences will Capricor Therapeutics (CAPR) attend in early 2025?

Capricor will attend three conferences: the Oppenheimer Healthcare Conference (February 12), the Barclays Global Healthcare Conference (March 11-13), and the ROTH Conference (March 16-18, 2025).

When is Capricor's (CAPR) presentation at the Oppenheimer Healthcare Conference?

Capricor will present at the Oppenheimer Healthcare Conference on February 12, 2025, from 12:00-12:30 p.m. ET. This is a virtual event.

What will Capricor (CAPR) discuss at these investor conferences?

Capricor management will present updates on deramiocel, their lead program for treating Duchenne muscular dystrophy (DMD), along with general scientific and corporate updates.

Where can investors find more information about Capricor's (CAPR) upcoming conference presentations?

Investors can find more information about the presentations on Capricor's website at http://capricor.com/news/events/.